Gene · 8764
Papers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
621 to 640 of 3,537
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Isolation and Characterization of Novel Canine Osteosarcoma Cell Lines from Chemotherapy-Naïve Patients. | Cells | 2023 | 37048099 | PubTator, text mining | PubMed |
| POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma. | Int J Mol Sci | 2023 | 37047824 | PubTator, text mining | PubMed |
| The Regulatory Axis of PD-L1 Isoform 2/TNF/T Cell Proliferation Is Required for the Canonical Immune-Suppressive Effects of PD-L1 Isoform 1 in Liver Cancer. | Int J Mol Sci | 2023 | 37047287 | PubTator, text mining | PubMed |
| Primary Cutaneous B-Cell Lymphomas with Large Cell Morphology: A Practical Review. | Int J Mol Sci | 2023 | 37047176 | PubTator, text mining | PubMed |
| A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV. | Cureus | 2023 | 37041924 | PubTator, text mining | PubMed |
| BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia. | Cancer Immunol Immunother | 2023 | 37041226 | PubTator, text mining | PubMed |
| Oncolytic virotherapy: basic principles, recent advances and future directions. | Signal Transduct Target Ther | 2023 | 37041165 | PubTator, text mining | PubMed |
| Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy. | Research (Wash D C) | 2023 | 37040283 | PubTator, text mining | PubMed |
| Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment. | Hemasphere | 2023 | 37038467 | PubTator, text mining | PubMed |
| Comprehensive analysis of cuproptosis-related immune biomarker signature to enhance prognostic accuracy in gastric cancer. | Aging (Albany NY) | 2023 | 37036489 | PubTator, text mining | PubMed |
| Immune microenvironment and clinical feature analyses based on a prognostic model in lymph node-positive breast cancer. | Front Oncol | 2023 | 37035163 | PubTator, text mining | PubMed |
| Genetic deletion of HVEM in a leukemia B cell line promotes a preferential increase of PD-1- stem cell-like T cells over PD-1+ T cells curbing tumor progression. | Front Immunol | 2023 | 37033927 | PubTator, text mining | PubMed |
| Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. | Signal Transduct Target Ther | 2023 | 37032379 | PubTator, text mining | PubMed |
| A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma. | BMC Gastroenterol | 2023 | 37024802 | PubTator, text mining | PubMed |
| A novel 7-chemokine-genes predictive signature for prognosis and therapeutic response in renal clear cell carcinoma. | Front Pharmacol | 2023 | 37021054 | PubTator, text mining | PubMed |
| BET Inhibition Sensitizes Immunologically Cold Rb-Deficient Prostate Cancer to Immune Checkpoint Blockade. | Mol Cancer Ther | 2023 | 37014264 | PubTator, text mining | PubMed |
| Clinical significance of nonerythrocytic spectrin Beta 1 (SPTBN1) in human kidney renal clear cell carcinoma and uveal melanoma: a study based on Pan-Cancer Analysis. | BMC Cancer | 2023 | 37013511 | PubTator, text mining | PubMed |
| Development and validation of a tumor immune cell infiltration-related gene signature for recurrence prediction by weighted gene co-expression network analysis in prostate cancer. | Front Genet | 2023 | 37007952 | PubTator, text mining | PubMed |
| Pathological fracture due to primary bone lymphoma in a patient with a history of prostate cancer: A case report and review of literature. | Front Oncol | 2023 | 37007154 | PubTator, text mining | PubMed |
| BTG2 and SerpinB5, a novel gene pair to evaluate the prognosis of lung adenocarcinoma. | Front Immunol | 2023 | 37006240 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8764/papers?page=32